Lilly’s Arxxant Granted Priority Review For Diabetic Retinopathy
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III trials are ongoing for additional indications for the protein kinase C-beta inhibitor ruboxistaurin.
You may also be interested in...
Looking For More Data: Lilly’s Arxxant Gets “Approvable” Letter
Lilly is hopeful that data from an ongoing study will avoid the need for an additional trial.
Looking For More Data: Lilly’s Arxxant Gets “Approvable” Letter
Lilly is hopeful that data from an ongoing study will avoid the need for an additional trial.
Lilly’s Arxxant To Be Co-Promoted With Alcon
An FDA decision on the potential first-in-class diabetic retinopathy treatment is expected next month.